logo-loader
CytoDyn

CytoDyn CEO talks about latest HIV trial featuring its flagship drug, leronlimab

CytoDyn Inc CEO Dr. Nader Pourhassan tells Proactive Investors the Washington-based biotech has teaming up with the Thai Red Cross AIDS Research Centre (TRCARC) to conduct a pre-exposure prophylaxis clinical trial of leronlimab (PRO 140) in subjects at high risk of HIV infection.

The CEO outlines differences between CytoDyn's leronlimab and the only product that is FDA approved to prevent HIV, Gilead Sciences' (NASDAQ:GILD) Truvada.

Quick facts: CytoDyn

Price: $0.42

Market: OTCQB
Market Cap: $152.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

6 days, 17 hours ago

2 min read